Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0.00 | $0.00 | $115M | $48.5M |
| Revenue growth | — | — | — | — | — | — | — | — | -57.7% |
| Operating income | -$6.65M | -$149M | -$186M | -$234M | -$216M | -$219M | -$184M | -$59.9M | -$171M |
| Operating margin | — | — | — | — | — | — | — | -52.2% | -352.2% |
| Net income | -$6.77M | -$147M | -$180M | -$243M | -$234M | -$229M | -$180M | -$56.5M | -$170M |
| Net margin | — | — | — | — | — | — | — | -49.3% | -351.5% |
| EPS (diluted) | -$0.74 | -$22.59 | -$3.29 | -$3.55 | -$3.13 | -$2.71 | -$1.18 | -$0.25 | -$0.75 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.75M | -$51.0M | -$145M | -$176M | -$189M | -$187M | -$159M | -$3.47M | -$171M |
| Capital expenditures | — | $3.49M | $2.97M | $1.50M | $1.55M | $410K | $0.00 | $0.00 | $79.0K |
| Free cash flow | — | -$54.5M | -$148M | -$178M | -$190M | -$187M | -$159M | -$3.47M | -$171M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $315K | $105M | $135M | $486M | $183M | $112M | $32.1M | $46.1M | $37.7M |
| Total assets | — | $239M | $427M | $539M | $344M | $272M | $312M | $315M | $172M |
| Total liabilities | — | $21.1M | $74.1M | $219M | $222M | $260M | $249M | $286M | $295M |
| Long-term debt | — | — | $28.5M | $28.7M | $29.1M | $12.0M | $814K | $0.00 | — |
| Shareholders' equity | -$6.86M | -$120M | $352M | $321M | $121M | $12.1M | $62.8M | $29.5M | -$123M |
| Retained earnings | — | -$154M | -$334M | -$578M | -$812M | -$1.03B | -$1.21B | -$1.27B | -$1.44B |
| Shares (wtd avg diluted) | — | 8.05M | 54.7M | 68.5M | 74.8M | 84.6M | 153M | 226M | 229M |
Every figure is extracted from Gossamer Bio, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.